We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
Liraglutide 3.0 mg works safely and effectively for weight loss in different racial groups
AI simplified
Abstract
Weight loss with liraglutide 3.0 mg was statistically significant across all racial subgroups, with an average loss of 7.7% for white participants.
- Liraglutide 3.0 mg was associated with significant mean weight loss compared to placebo in white (7.7% vs. 2.3%), black/African-American (6.3% vs. 1.4%), Asian (6.3% vs. 2.5%), and other (7.3% vs. 0.49%) participants.
- The treatment effects on weight and cardiovascular risk markers did not show dependence on race, as indicated by statistical tests.
- Adverse events were similar across all racial subgroups, suggesting a consistent safety profile.
AI simplified
Key numbers
7.7%
Weight Loss in White Participants
Weight loss with liraglutide 3.0 mg vs. placebo
6.3%
Weight Loss in Black/African-American Participants
Weight loss with liraglutide 3.0 mg vs. placebo
6.3%
Weight Loss in Asian Participants
Weight loss with liraglutide 3.0 mg vs. placebo